| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (NCT00082810) | National Cancer Institute (NCI) | 2004-03-01 |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia (NCT00077922) | National Cancer Institute (NCI) | 2004-02-29 |
| Biology Studies of Hematologic Cancers (NCT00923442) | National Cancer Institute (NCI) | 2004-02-24 |
| Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II (NCT00099112) | National Cancer Institute (NCI) | 2004-02-01 |
| CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer (NCT00079235) | National Cancer Institute (NCI) | 2004-02-01 |
| Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00079456) | National Cancer Institute (NCI) | 2004-02-01 |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00079378) | National Cancer Institute (NCI) | 2004-02-01 |
| Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors (NCT00080990) | National Cancer Institute (NCI) | 2004-02-01 |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) (NCT00071994) | National Cancer Institute (NCI) | 2004-02-01 |
| Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (NCT00079274) | National Cancer Institute (NCI) | 2004-02-01 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (NCT00077454) | National Cancer Institute (NCI) | 2004-02-01 |
| Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus (NCT00076752) | National Cancer Institute (NCI) | 2004-01-30 |
| Eligibility Screening for the NIH Intramural Research Program Clinical Protocols (NCT00026754) | National Cancer Institute (NCI) | 2004-01-14 |
| Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer (NCT00965276) | National Cancer Institute (NCI) | 2004-01-13 |
| Genetics of Familial Testicular Cancer (NCT00342537) | National Cancer Institute (NCI) | 2004-01-02 |
| Oblimersen in Treating Patients With Merkel Cell Carcinoma (NCT00079131) | National Cancer Institute (NCI) | 2004-01-01 |
| 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors (NCT00079014) | National Cancer Institute (NCI) | 2004-01-01 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder (NCT00085410) | National Cancer Institute (NCI) | 2004-01-01 |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT00075881) | National Cancer Institute (NCI) | 2004-01-01 |
| Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (NCT00074490) | National Cancer Institute (NCI) | 2004-01-01 |
| Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer (NCT00075751) | National Cancer Institute (NCI) | 2004-01-01 |
| GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00078962) | National Cancer Institute (NCI) | 2004-01-01 |
| Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer (NCT00062101) | National Cancer Institute (NCI) | 2004-01-01 |
| Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT00075400) | National Cancer Institute (NCI) | 2004-01-01 |
| Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT00079170) | National Cancer Institute (NCI) | 2004-01-01 |
| 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction (NCT00077545) | National Cancer Institute (NCI) | 2004-01-01 |
| 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies (NCT00077181) | National Cancer Institute (NCI) | 2004-01-01 |
| FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma (NCT00079443) | National Cancer Institute (NCI) | 2004-01-01 |
| Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma (NCT00079144) | National Cancer Institute (NCI) | 2004-01-01 |
| FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00077194) | National Cancer Institute (NCI) | 2004-01-01 |
| Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia (NCT00077467) | National Cancer Institute (NCI) | 2004-01-01 |
| Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer (NCT00079326) | National Cancer Institute (NCI) | 2004-01-01 |
| Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma (NCT00079339) | National Cancer Institute (NCI) | 2004-01-01 |
| Collection of Tissue Samples for Study of Multidrug Resistance (NCT00880503) | National Cancer Institute (NCI) | 2003-12-19 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00075439) | National Cancer Institute (NCI) | 2003-12-01 |
| Bevacizumab in Treating Young Patients With Refractory Solid Tumors (NCT00085111) | National Cancer Institute (NCI) | 2003-12-01 |
| CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00075647) | National Cancer Institute (NCI) | 2003-12-01 |
| Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma (NCT00075634) | National Cancer Institute (NCI) | 2003-12-01 |
| CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas (NCT00074243) | National Cancer Institute (NCI) | 2003-12-01 |
| Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00072566) | National Cancer Institute (NCI) | 2003-12-01 |
| Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00085124) | National Cancer Institute (NCI) | 2003-12-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer (NCT00077298) | National Cancer Institute (NCI) | 2003-12-01 |
| Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma (NCT00093782) | National Cancer Institute (NCI) | 2003-12-01 |
| Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme (NCT00075491) | National Cancer Institute (NCI) | 2003-12-01 |
| Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00088959) | National Cancer Institute (NCI) | 2003-12-01 |
| Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies (NCT00341263) | National Cancer Institute (NCI) | 2003-11-21 |
| Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis (NCT00646555) | National Cancer Institute (NCI) | 2003-11-20 |
| Recontacting Participants in the Observing Protein and Energy Nutrition (OPEN) Study: Re-OPEN (NCT00339677) | National Cancer Institute (NCI) | 2003-11-06 |
| Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors (NCT00074321) | National Cancer Institute (NCI) | 2003-11-01 |
| Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma (NCT00070525) | National Cancer Institute (NCI) | 2003-11-01 |
| Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer (NCT00075504) | National Cancer Institute (NCI) | 2003-11-01 |
| Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (NCT00058461) | National Cancer Institute (NCI) | 2003-11-01 |
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma (NCT00070447) | National Cancer Institute (NCI) | 2003-11-01 |
| A Phase II Study of UCN-01 in Metastatic Melanoma (NCT00072189) | National Cancer Institute (NCI) | 2003-11-01 |
| Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer (NCT00068692) | National Cancer Institute (NCI) | 2003-10-15 |
| Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer (NCT00071058) | National Cancer Institute (NCI) | 2003-10-01 |
| S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (NCT00068783) | National Cancer Institute (NCI) | 2003-10-01 |
| Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00055757) | National Cancer Institute (NCI) | 2003-10-01 |
| Vaccine Therapy in Treating Patients With Metastatic Breast Cancer (NCT00071942) | National Cancer Institute (NCI) | 2003-10-01 |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (NCT00072137) | National Cancer Institute (NCI) | 2003-10-01 |
| Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer (NCT00060437) | National Cancer Institute (NCI) | 2003-10-01 |
| GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer (NCT00068588) | National Cancer Institute (NCI) | 2003-10-01 |
| Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00053183) | National Cancer Institute (NCI) | 2003-10-01 |
| Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma (NCT00072150) | National Cancer Institute (NCI) | 2003-10-01 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers (NCT00074308) | National Cancer Institute (NCI) | 2003-10-01 |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors (NCT00074022) | National Cancer Institute (NCI) | 2003-10-01 |
| Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma (NCT00072163) | National Cancer Institute (NCI) | 2003-10-01 |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas (NCT00069238) | National Cancer Institute (NCI) | 2003-09-19 |
| Cervical Cancer Early Endpoints and Determinants (NCT00339989) | National Cancer Institute (NCI) | 2003-09-12 |
| Harvesting Cells for Experimental Cancer Treatments (NCT00068003) | National Cancer Institute (NCI) | 2003-09-08 |
| GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT00070551) | National Cancer Institute (NCI) | 2003-09-01 |
| Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma (NCT00072124) | National Cancer Institute (NCI) | 2003-09-01 |
| Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma (NCT00072085) | National Cancer Institute (NCI) | 2003-09-01 |
| Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer (NCT00057941) | National Cancer Institute (NCI) | 2003-09-01 |
| Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer (NCT00070252) | National Cancer Institute (NCI) | 2003-09-01 |
| Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors (NCT00072436) | National Cancer Institute (NCI) | 2003-09-01 |
| Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer (NCT00066742) | National Cancer Institute (NCI) | 2003-09-01 |
| Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene (NCT00072111) | National Cancer Institute (NCI) | 2003-09-01 |
| Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer (NCT00069160) | National Cancer Institute (NCI) | 2003-09-01 |
| Evaluating Serum Sex Steroid Hormones (NCT00340756) | National Cancer Institute (NCI) | 2003-08-06 |
| Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy (NCT00066846) | National Cancer Institute (NCI) | 2003-08-01 |
| Chordoma Family Study (NCT00410670) | National Cancer Institute (NCI) | 2003-08-01 |
| Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening (NCT00131950) | National Cancer Institute (NCI) | 2003-08-01 |
| Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections (NCT00059878) | National Cancer Institute (NCI) | 2003-08-01 |
| Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00058097) | National Cancer Institute (NCI) | 2003-08-01 |
| Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer (NCT00078910) | National Cancer Institute (NCI) | 2003-08-01 |
| Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies (NCT00070239) | National Cancer Institute (NCI) | 2003-08-01 |
| Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer (NCT00070265) | National Cancer Institute (NCI) | 2003-08-01 |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer (NCT00059813) | National Cancer Institute (NCI) | 2003-08-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Radiation Therapy and the Natural History of Childhood Cancers (NCT00064883) | National Cancer Institute (NCI) | 2003-07-28 |
| Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk (NCT00043472) | National Cancer Institute (NCI) | 2003-07-09 |
| Analyses of Human Samples Collected in Clinical Trials (NCT00339664) | National Cancer Institute (NCI) | 2003-07-02 |
| Cilengitide in Treating Children With Refractory Primary Brain Tumors (NCT00063973) | National Cancer Institute (NCI) | 2003-07-01 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors (NCT00066651) | National Cancer Institute (NCI) | 2003-07-01 |
| Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer (NCT00066768) | National Cancer Institute (NCI) | 2003-07-01 |
| Anidulafungin in Treating Immunocompromised Children With Neutropenia (NCT00068471) | National Cancer Institute (NCI) | 2003-07-01 |
| Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer (NCT00066625) | National Cancer Institute (NCI) | 2003-07-01 |
| Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (NCT00068315) | National Cancer Institute (NCI) | 2003-07-01 |